Adding the drug abiraterone to standard hormone therapy helps people with prostate cancer that has spread to other parts of the body to live longer. Results from the STAMPEDE trial were presented at the European Society for Medical Oncology Congress in Paris last week. For more on this, please click on the following link to the UCL News feed: https://www.mrcctu.ucl.ac.uk/news/news-stories/2022/september/adding-abiraterone-to-standard-therapy-helps-people-with-metastatic-prostate-cancer-to-live-longer/ ...
News
STAMPEDE
MRC Clinical Trials Unit at UCL
2nd Floor
90 High Holborn
London
WC1V 6LJ
Email: mrcctu.stampede@ucl.ac.uk